NexImmune, Inc. announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune?s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. The extension includes an additional $300,000 grant, funded by JDRF to Yale, as a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D). The JDRF award will continue to fund efforts to investigate the use of NexImmune?s AIM nanoparticles in combination with a murine surrogate of teplizumab, which has been shown to modulate the pathogenic immune response acutely.

Combining anti-CD3 treatment with NexImmune?s injectable therapy provides the opportunity to target and modulate T1D antigen-specific T cells and potentially maintain their non-responsiveness with the goal to extend benefit and induce tolerance. NexImmune?s nanoparticles have the potential to further enhance the effect of anti-CD3 through modulation of the residual T1D specific T cells.